Exploration of differences in tolerance between Caucasian and Asian non-small cell lung cancer patients receiving palliative chemotherapy with carboplatin and paclitaxel

Sydney Cancer Centre0 个研究点目标入组 120 人开始时间: 2011年1月6日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Asian or Caucasian patients.
•- Histologically confirmed advanced non-small cell lung cancer patients
•- receiving chemotherapy with carboplatin AUC 6 and paclitaxel 175 mg/m2
•- Age greater than or equal to 18.
•- Eastern Cooperative Oncology Group (ECOG)Performance Status of 0-2.
•- Ability to comply with the planned procedures and provide written evidence of informed consent.
•- Adequate haematology and biochemistry. (Haemoglobin>100 g/L, White blood cell count >4.0 x 109/L, neutrophil count > 1.5 × 109, platelets >100 x 109/L; Aspartate transaminase (AST), Alanine transaminase (ALT) and bilirubin < 1.5 x ULN (AST, ALT < 5 x upper limit of normal in case liver metastases); calculated creatinine clearance according to Corkroft formula > 60 ml/min.

•- Patients who require dose adjustment.
•- Clinical evidence of active brain metastases.
•- Suspected or documented bone marrow involvement.
•- Significant intercurrent illness including active infection, inflammatory bowel disease or other uncontrolled autoimmune disease.
•- The requirement for ongoing systemic treatment with corticosteroids or other immunosuppressive therapy.
•- Patients who have had chemotherapy 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
•- Ongoing major side effects from radiology.
•- Other active malignancy.
•- Known allergy to any of the investigational agents.

发起方

Sydney Cancer Centre